The company states: “Neuphoria Therapeutics (NEUP) issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP full of deception and distraction to deflect attention from its own limitations and its handpicked nominees’ shortcomings. The Company urges stockholders to trust Neuphoria’s commitment to transparency and value creation over what it believes are Lynx1’s fabrications and misdirection by voting FOR Neuphoria’s nominees Peter Miles Davies and David Wilson on the WHITE proxy card and voting WITHHOLD on both of Lynx1’s nominees.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP:
- Neuphoria Therapeutics urges stockholders to vote for company nominees
- Neuphoria initiates strategic review, confirms receipt of indication of interest
- Neuphoria Therapeutics Declares Dividend Rights Plan
- Biotech Alert: Searches spiking for these stocks today
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!